xtandi
astellas pharma europe b.v. - enzalutamid - nowotwory stercza - terapia endokrynologiczna - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
controloc 20 20 mg tabletki dojelitowe
takeda pharma sp. z o.o. - pantoprazolum natricum sesquihydricum - tabletki dojelitowe - 20 mg
matrifen 100 mikrogramów/godzinę system transdermalny 100 mcg/h system transdermalny
takeda pharma sp. z o.o. - fentanylum - system transdermalny - 100 mcg/h
matrifen 75 mikrogramów/godzinę system transdermalny 75 mcg/h system transdermalny
takeda pharma sp. z o.o. - fentanylum - system transdermalny - 75 mcg/h
matrifen 25 mikrogramów/godzinę system transdermalny 25 mcg/h system transdermalny
takeda pharma sp. z o.o. - fentanylum - system transdermalny - 25 mcg/h
matrifen 50 mikrogramów/godzinę system transdermalny 50 mcg/h system transdermalny
takeda pharma sp. z o.o. - fentanylum - system transdermalny - 50 mcg/h
matrifen 12 mikrogramów/godzinę system trandermalny 12 mcg/h system transdermalny
takeda pharma sp. z o.o. - fentanylum - system transdermalny - 12 mcg/h
xospata
astellas pharma europe b.v. - gilteritinib fumaran - białaczka, szpikowe, ostre - Środki przeciwnowotworowe - xospata jest wskazany w monoterapii w leczeniu dorosłych pacjentów z nawrotem lub oporną na leczenie ostrej białaczki szpikowej (aml) z mutacją flt3 w .
nubeqa
bayer ag - darolutamide - nowotwory gruczołu krokowego, odpornego Łożysko - terapia endokrynologiczna - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
abiraterone accord
accord healthcare s.l.u. - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.